Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura

The therapy of ITP has recently been revolutionized with the introduction of thrombopoeitin stimulating agents. However, these medications are known to increase the platelet count only while the medication is being administered, with a rapid fall of the platelet count to baseline pre-therapy levels on discontinuation. We report the case of a patient with chronic refractory ITP who has attained a prolonged remission after a short course of eltrombopag, with normalization of the platelet count, which is sustained 8 months after discontinuation of the medication.